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TherapeuticThe monoclonal antibody against the AC133 epitope of CD133 has been widely used as a cell surface mar-
ker of cancer stem cells in several different cancer types. Here, we describe the isolation and character-
isation of two RNA aptamers, including the smallest described 15 nucleotide RNA aptamer, which
specifically recognise the AC133 epitope and the CD133 protein with high sensitivity. As well, both these
aptamers show superior tumour penetration and retention when compared to the AC133 antibody in a 3-
D tumour sphere model. These novel CD133 aptamers will aid future development of cancer stem cell
targeted therapeutics and molecular imaging.
Crown Copyright  2012 Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
CD133, also known as Prominin-1, is a pentaspan, highly glycos-
ylated, membrane glycoprotein that is associated with cholesterol
in the plasma membrane [1,2]. Though this protein is known to de-
fine a broad population of cells, including somatic stem and pro-
genitor cells, and is expressed in various developing epithelial
and differentiated cells, its exact function is still being elucidated.
It has, however, been linked to the Notch-signalling pathway
which is critical for binary cell fate, differentiation of intestinal epi-
thelium, and lymphopoiesis [3]. CD133 has gained its prominence
in the cancer research field due to its reported role as a marker of
cancer stem cells (CSCs) in glioblastomas [4]. Indeed, growing evi-
dence has shown that CD133 is an important cell surface marker
for CSCs in a variety of solid cancers, including those of the brain,
prostate, pancreas, melanoma, colon, liver, lung and ovarian can-cers [5] by virtue of the enhanced tumourigenic potential of
CD133+ cells versus their negative counterparts in immunodefi-
cient mice [6].
Most of the work in isolating CD133+ putative cancer stem cell
subpopulation from the bulk cancer cells utilises one monoclonal
antibody, AC133 [7]. However, there has been some controversy
regarding the notion that CD133 can be used as a marker for CSCs,
as investigators from independent laboratories showed that the
CD133 cells are also tumourigenic in immunocompromised mice
[8–10]. This contention is further complicated by the near ubiqui-
tous expression of CD133 on non-CSCs as well as CSCs, especially in
tumours of the colon [11]. A recent study has shed some light on
this, with a conformational change postulated to hide an epitope
on the second extracellular membrane loop of CD133 during the
differentiation process [5]. Kemper and co-workers suggested that
the CD133 protein becomes differentially folded as a result of gly-
cosylation, thus masking the AC133 epitope. These results were
further supported by later studies [5,12] which suggested that
the AC133 epitope, rather than the complete CD133 protein, is
the marker for CSCs. As well, a recent report has shown that the
AC133 epitope is lost upon cell differentiation, suggesting that this
epitope is a marker of primitive cells [5]. While the AC133 epitope
has been shown to be a marker for CSCs, not all cells positive for
S. Shigdar et al. / Cancer Letters 330 (2013) 84–95 85the AC133 epitope are CSCs. In fact, the first description of this epi-
tope was by Yin et al. in 1997, who described this as a marker of
haematopoietic stem and progenitor cells [13]. However, the
expression of AC133 on these cells is approximately 1000-fold low-
er than that observed in CSCs [14]. Despite the on-going debate of
the utility of using AC133 to identify cancer stem cells, a retrospec-
tive study on colorectal patients showed that a high level of AC133
expression was associated with a poorer prognosis [15], though the
sole use of the AC133 antibody is not recommended as it is thought
to underestimate the level of CD133 expression [1,16].
AC133-positive cells have been shown to have an increased
resistance to radiation therapy due to activation of the DNA dam-
age checkpoint proteins, and an increased chemoresistance due to
an increased Akt/PKB and Bcl-2 cell survival response [17]. These
data suggest that a more targeted response is required to eradicate
this population of cells, especially given the increasing evidence
regarding the roles that CSCs play in the relapse of cancer after ini-
tial treatments. Immunotherapy has had a great impact on the
treatment of cancer in recent years [18,19]. However, the use of
antibodies, even humanised antibodies, can lead to adverse side ef-
fects with fatal consequences [20]. This has led to the search for
‘bigger and better’ options. There have been several attempts to
use nucleic acids as therapeutics though these have met with dis-
appointing results, not least because of the failure of these nucleic
acids to enter the cell [21]. The reports in 1990 by two separate
groups describing the generation of nucleic acids that can bind tar-
get molecules in the same manner as antibodies seemed to be the
answer [22,23]. These chemical antibodies, termed aptamers, have
been increasingly utilised for clinical applications recently. Indeed,
one RNA aptamer has been approved by the FDA and several more
are in clinical trials [21,24]. The increased interest in these apta-
mers is due to the fact that they exhibit no immunogenicity, little
batch-to-batch variation due to being chemically synthesised, and
are more stable than conventional antibodies. Due to their small
size, aptamers also show superior tumour penetration. One impor-
tant feature of these chemical antibodies is their versatility as they
can be attached to nanoparticles, drugs, imaging agents or other
nucleic acid therapeutics without loss-of-function [25,26]. This
functionalisation is leading to new and more targeted therapies,
with fewer side effects than current treatment modalities [25].
When compared to conventional treatment which is largely a pas-
sive process, targeted delivery systems are much more effective.
For an aptamer to be an effective drug delivery agent, the aptamer
must be efficiently internalised upon binding to its target on the
cell surface [27].
In this study, we performed iterative rounds of an in vitro selec-
tion process, known as the systematic evolution of ligands by
exponential enrichment (SELEX), to identify RNA aptamers that
specifically bind to CD133. Further studies identified one aptamer,
CD133-A15, specifically bound to the same epitope as the AC133
antibody, while the other aptamer, CD133-B19, bound to the extra-
cellular domain of the CD133 protein. These aptamers were effi-
ciently internalised into CD133-positive cancer cells and showed
superior penetration of three-dimensional tumour sphere.2. Materials and methods
2.1. Cell lines and cell culture
The cell lines of human origin used in this study were purchased from American
type Culture Collection. They are human colorectal cancer HT-29; human hepato-
cellular carcinoma Hep3B; human glioblastoma multiform carcinoma T98G; human
embryonic kidney cells HEK293T; human ductal breast carcinoma, T47D; human
lung adenocarcinoma, A549; human ovarian teratocarcinoma, PA-1; human hepa-
toma, PLC/PRC/5; and human prostate carcinoma, DU145. Cells were grown and
maintained in culture with Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen,Victoria, Australia) supplemented with 10% foetal calf serum (FCS) (HEK293T and
HT-29), or Minimum Essential Medium (MEM) (Invitrogen) supplemented with
10% FCS (Hep3B and T98G). Cells were maintained at 37 C in a 5% CO2 atmosphere.
2.2. Protein expression and cell SELEX
Human CD133 cDNA was purchased from Invitrogen and cloned into a mamma-
lian expression vector, pcDNA 3.1/V5-His-TOPO (Invitrogen). The recombinant 6
Histine-tagged CD133 was transiently expressed in HEK293T cells. Briefly, HEK293T
cells were seeded in 100 mm or 60 mm dishes to reach 70% confluency after 24 h
incubation, and transfected with a total of 24 or 8 lg, respectively, of CD133 using
Lipofectamine 2000 (Invitrogen Life Technologies) in antibiotic-free medium
according to the manufacturer’s instructions. Following a 72 h incubation, the
transfected cells were used as the target for cell SELEX. Successful transfection
and expression of the recombinant CD133 were confirmed using flow cytometry
and the AC133-APC antibody (Miltenyl Biotech) prior to each round of SELEX.
2.3. SELEX selection
A DNA library containing a central 40-nt randomised sequence (50-TAA TAC GAC
TCA CTA TAG GGA GAC AAG AAT AAA CGC TCA A-N40-TTC GAC AGG AGG CTC ACA
ACA GGC, with the T7 RNA polymerase promoter sequence underlined) was syn-
thesised (GeneWorks, Australia). The double stranded DNA pool was generated
from the original synthetic library via a large scale PCR using primers flanking
the randomised sequence, 50-TAA TAC GAC TCA CTA TAG GGA GAC AAG AAT AAA
CGC TCA A-30 and 50-GCC TGT TGT GAG CCT CCT GTC GAA-30 . A portion of the
large-scale PCR products (1014 sequences) was used as a template for in vitro tran-
scription to produce the initial 20-fluoropyrimidine modified RNA pool using a
Durascribe T7 Transcription kit (EPICENTRE Biotechnologies, USA). For SELEX,
RNA, at a concentration of 5 lM for initial selection or 1 lM for each iterative
rounds, was diluted in 100 lL of wash buffer (Dulbecco’s phosphate buffered saline
containing 2.5 mM MgCl2) and denatured at 85 C for 5 min, allowed to cool to
room temperature for 10 min, and annealed at 37 C for 15 min, before incubation
with the target protein expressed in HEK293T cells for 1 h at 4 C. Following incu-
bation and extensive washes, the bound RNA was reverse transcribed using Super-
Script III Reverse Transcriptase (Invitrogen), followed by PCR amplification and
in vitro transcription and used for the next round of SELEX. Counter-selection steps
were included from round 4, using a His-tagged irrelevant protein expressed in
HEK293T cells, to decrease the enrichment of species specifically recognising the
His-tag, the HEK293T cells or the tissue culture plate. The number of PCR amplifi-
cation cycles was also optimised to prevent over-amplification of non-specific ‘‘par-
asite’’ PCR products. In addition, the stringency of the selection process was
enhanced to promote the selection of high-affinity aptamers through adjustments
to aptamer concentration, incubation times, and the number of washes. To acquire
aptamers of high specificity, the number of cells used was progressively decreased
while the washing stringency increased during the progression of SELEX, with neg-
ative selections included from round four. Enrichment was monitored using restric-
tion fragment length polymorphism (RFLP) and flow cytometry using live cells.
2.4. RFLP analysis
The enrichment of aptamer candidates during selection was determined by
RFLP. Briefly, RFLP was performed as previously described [28,29], with minor mod-
ifications. Approximately 5 ng of cDNA from iterative cycles was amplified by PCR
for eight cycles. The amplified DNA was digested with four restriction enzymes,
Afa I, Alu I, Hha I and Xsp I that recognise four nucleotides (frequent cutters) in Buf-
fer T supplied by the manufacturer (Takara) with 0.1% (w/v) bovine serum albumin
at 37 C overnight. Following the overnight digestion, the DNA was heated to 65 C,
cooled on ice, and separated via electrophoresis on a native 20% polyacrylamide gel
in TBE buffer. The gel was then stained in GelStar and visualised using a standard
gel imaging system.
2.5. Flow cytometry assays
Cells were harvested at 80% confluence with trypsin digestion and resuspended
in washing buffer (DPBS with 2.5 mM MgCl2) and enumerated. Following centrifu-
gation (1000g for 5 min), the cell pellet was resuspended in DMEM with 10% FCS
and diluted to 1  106/mL. The cells were allowed to re-establish their cell surface
markers for a period of 2 h prior to binding analysis. To confirm aptamer binding to
the target protein, RNA from iterative rounds were labelled at the 30-ends with fluo-
rescein isothiocyanate (FITC) according to a previously described method [30]. Am-
ber tubes were used throughout to minimise photo-bleaching. Briefly, samples
were oxidised with sodium periodate. The oxidation was terminated with the addi-
tion of 10 mM ethylene glycol, followed by ethanol precipitation. FITC was added at
a 30-M excess, and the reaction was completed overnight at 4 C. 1 lM of FITC-la-
belled RNA was incubated with trypsinised 5  105 HEK293T transfected with
CD133 protein or non-transfected HEK293T cells in 100 lL of binding buffer (DPBS
with 2.5 mMMgCl2, 0.1 mg/mL tRNA and 0.1 mg/mL salmon sperm DNA) for 1 h on
ice, followed by washing three times and resuspension in 300 lL of binding buffer.
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Dickinson) by counting 50,000 events for each sample. The FITC-labelled RNA from
the unselected library was used to determine non-specific binding. The binding for
each round was calculated after subtracting the mean fluorescence intensity of the
binding of round zero RNA to target cells as well as that for binding to negative con-
trol cells according to a method described by Ellington and colleagues [31].2.6. Cloning, sequencing and structural analysis of selected aptamers
Following RFLP and flow cytometric analyses of iterative rounds, round six
demonstrated a sufficient enrichment of RNA sequences that selectively recognised
the target protein. This enriched pool was amplified by PCR for ten cycles and the
PCR products were cloned into the plasmid pCR4-TOPO (Invitrogen). Plasmid
DNA from individual clones was prepared and their sequence determined using
an automated DNA sequencing procedure. The aptamer sequences were analysed
using ClustalX2 [32]. Secondary structures were predicted using the program RNA-
fold [33].2.7. Determination of aptamer affinity
The dissociation constant (KD) of successful 20-fluoropyrimidine RNA aptamer
species to native CD133 expressed on the cell surface was determined using flow
cytometry. HEK293T cells transfected with CD133 protein, or non-transfected
HEK293T cells (5  105) were first incubated with blocking buffer for 1 h on ice
(binding buffer containing 0.2% (w/v) sodium azide) followed by two washes with
binding buffer prior to incubation with serial concentrations (approximately 10-
fold above and below the apparent KD) of FITC-labelled aptamer in a 100 lL volume
of binding buffer for 1 h on ice. The cells were washed three times with binding buf-
fer, resuspended in 150 lL binding buffer and subjected to flow cytometric analy-
ses. The FITC-labelled unselected library was used as a negative control. The
mean fluorescence intensity (MFI) of the unselected library was subtracted from
that of the aptamer-target cell to generate the MFI of specific binding. The KD for
each aptamer was determined by Scatchard analysis according to the following
equation:
½Bound aptamer=½aptamer ¼ ð1=KDÞ  ½bound aptamer þ ð½Ttot=KDÞ
where [T]tot represents the total target concentration.2.8. Aptamer truncation and determination of specificity
To generate the truncated aptamers, the sense and antisense DNA oligonucleo-
tides of desired sequences were synthesised. CD133-A58 (1st Truncation) was de-
rived from a sense oligonucleotide, 50-TAA TAC GAC TCA CTA TAG AGA CAA GAA
TAA ACG CTC AAC CCA CCC TCC TAC ATA GGG AGG AAC GAG TTA CTA TAG-30 ,
and antisense oligonucleotide, 50-CTA TAG TAA CTC GTT CCT CCC TAT GTA GGA
GGG TGG GTT GAG CGT TTA TTC TTG TCT C-30; CD133-A35 (2nd Truncation) was
derived from a sense oligonucleotide: 50-TAA TAC GAC TCA CTA TAG CTC AAC
CCA CCC TCC TAC ATA GGG AGG AAC GAG T-30and an antisense oligonucleotide,
50-ACT CGT TCC TCC CTA TGT AGG AGG GTG GGT TGA GC-30; CD133-A21 (3rd Trun-
cation) was derived from a sense oligonucleotide, 50-TAA TAC GAC TCA CTA TAC
CAC CCT CCT ACA TAG GGT GG-30 and an antisense oligonucleotide, 50-CCA CCC
TAT GTA GGA GGG TGG-30; and CD133-A15 (4th Truncation) was derived from a
sense oligonucleotide, TAA TAC GAC TCA CTA TAC CCT CCT ACA TAG GG-30 and
an antisense oligonucleotide, 50-CCC TAT GTA GGA GGG-30 . CD133-B19 (1st Trunca-
tion) was derived from a sense oligonucleotide 50-TAA TAC GAC TCA CTA TAC AGA
ACG TAT ACT ATT CTG-30 and an antisense oligonucleotide, 50-CAG AAT AGT ATA
CGT TCT G-30 (T7 RNA promoter sequence is underlined). The relevant pairs of oli-
gonucleotides were mixed in equal molar ratios in 1  PEI buffer (0.1 M Tris–HCl pH
8, 0.1 M MgCl2 0.5 M NaCl and 0.1 M dithiothreitol), heated for 5 min at 90 C and
cooled slowly to room temperature prior to ethanol precipitation. In vitro transcrip-
tion and FITC-labelling was performed as described above. The final truncations of
these clones (CD133-A15 and CD133-B19), 50-DY647-CCC UCC UAC AUA GGG-dT-30
and 50-DY647-CAG AAC GUA UAC UAU UCU G-dT-30 , were also chemically synthes-
ised with a 50-DY647 fluorescent tag and a 30-inverted deoxythymidine (Dharma-
con). The binding affinities of these two aptamers and a negative control aptamer
was determined by flow cytometric analysis using CD133 positive (HT-29 and
Hep3B) and CD133 negative cell lines (T98G and HEK293T). The blocking step
was performed at 4 C using blocking buffer containing 5% (v/v) foetal calf serum,
whilst the binding of the aptamers was performed at 37 C for 30 min. Furthermore,
the binding specificity of these aptamers was confirmed with additional CD133-po-
sitive (PA-1 and PLC/PRF/5) and -negative cell lines (A549, DU145 and T47D). Apta-
mers and antibody were incubated with the cells at 100 nM or 1:11 dilution as
previously described for 30 min at 37 C, washed three times and quantified using
the flow cytometer.2.9. Confocal microscopy
Twenty-four hours prior to labelling, cells were seeded at a density of 75,000
cells per cm2 in an 8-chamber slide (Lab-Tek II, Nunc). DY647-CD133-A15,
DY647-CD133-B19 and the control aptamer were prepared in the same manner
as for flow cytometry. Following removal of media, cells were incubated in blocking
buffer containing 5% (v/v) foetal calf serum at 37 C for 15 min, washed twice in
binding buffer prior to incubation with 200 nM aptamer for 30 min at 37 C. Bis-
benzimide Hoechst 33342 (3 lg/mL) (Sigma) was added to the cells during the final
15 min of incubation. The aptamer solution was removed and the cells washed
three times for 5 min each in binding buffer prior to visualisation using a FluoView
FV10i laser scanning confocal microscope (Olympus).
2.10. Inhibition of endocytosis
This was performed essentially as described for confocal microscopy with min-
or modifications. Briefly, cells were pre-treated with a potassium-depleted buffer
(50 mM HEPES, 140 mM NaCl, 2.5 mMMgCl2, and 1 mM CaCl2) for 1 h at 37 C prior
to incubation with the aptamers. These buffers were also used in the incubation
step with aptamers and all rinsing steps. The effectiveness of these treatments in
inhibiting endocytosis was evaluated by qualitatively characterising the internali-
sation of human transferrin conjugated to Alexa Fluor 488 (Invitrogen Life Technol-
ogies). Transferrin (5 lg/mL) was added to the cells following pre-treatment
followed by a 30 min incubation at 37 C. The cells were washed three times in their
respective buffers and visualised using the FluoView FV10i confocal microscope.
2.11. Tumour sphere preparation and incubation with aptamers and antibody
Two thousand HT29 and HEK293T cells were plated out in ultralow attachment
wells and allowed to form spheres for 7 days in DMEM/F12 media (Invitrogen Life
Technologies) containing 10 ng/mL epidermal growth factor, 10 ng/mL basic fibro-
blast growth factor, 50 lg/mL insulin and 100 units/mL B27. At 7 days, the spheres
were washed three times in PBS containing 2.5 mM MgCl2 and blocked for 20 min
using binding buffer. The spheres were then incubated with 100 nM of aptamer or
AC133 antibody (30 lM, Miltenyl Biotec) for 30 min, 60 min, 120 min, or 240 min.
Following each time point, the spheres were washed three times with PBS prior
to visualisation using the FluoView FV10i confocal microscope. To determine the
retention of aptamers within the tumour sphere, HT-29 tumour spheres were incu-
bated with CD133 aptamers or CD133 antibody for a total of 4 h, washed three
times in PBS, followed by incubation in sphere medium for a further 24 h before
being imaged.
2.12. Differentiation assay with sodium butyrate
Twenty-four hours prior to differentiation, HT-29 cells were seeded at a density
of 500,000 cells in a 12 well plate. Upon reaching 70% confluence, cells were treated
with 5 mM sodium butyrate for a total of 24 or 48 h and were then incubated with
either the AC133 antibody, CD133-A15 or CD133-B19 aptamer for 30 min at 37 C.
The AC133 antibody was used at a concentration of 30 lM as recommended by the
manufacturer. After washing with PBS, the binding of AC133 antibody or aptamers
was assessed using flow cytometric analysis.
2.13. Western blotting
HT-29 cells were treated with sodium butyrate as described in the previous sec-
tion. The expression of CD133 protein in HT-29 cells was analysed by Western anal-
ysis as previously described [34]. Fifteen microlitres of each sample was loaded
onto a 12% NuPAGE Bis–Tris mini gel (Invitrogen) along with a Precision Plus dual
colour protein standard (BioRad). Following electrophoresis for 45 min at 200 V, the
protein was transferred to a nitrocellulose membrane (Invitrogen) and blocked with
5% skimmed milk for 3 h at 25 C, before being incubated with either anti-b-actin
(Sigma) diluted 1:2000, or the anti-CD133 antibody, CD133/1 (clone W6B3C1, Mil-
tenyl Biotec) diluted 1:200 in 1% skimmed milk, overnight at 4 C. Chemilumines-
cence was detected using an ImageQuant™ LAS 4000 Biomolecular Imager (GE
Healthcare).
3. Results
3.1. Cell SELEX facilitates the selection of aptamers against cell surface
targets
CD133 is a complex pentaspan protein containing two extracel-
lular loops. To effectively select aptamers against only the extracel-
lular portion of the protein, it was necessary to devise a procedure
that allowed us to express CD133 so as to preserve its native con-
formation. To this end, we sought to transiently express the protein
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terminally His-tagged CD133 was transfected into HEK293T cells
and allowed to express for 72 h prior to SELEX experiments, with
expression confirmed by AC133 antibody staining. Similar to our
previous SELEX experiments [26], a random RNA library of approx-
imately 1  1014 species containing 20-fluoro-modified ribose on
all pyrimidines was incubated with HEK293T cells expressing hu-
man CD133. Unbound RNA was removed via several washing steps
prior to RT-PCR, and the process was repeated for a total of 12
rounds. Non-specific binding was eradicated through negative
selection using an irrelevant His-tagged protein transfected into
HEK293T cells. Non-radioactive RFLP was performed to confirm
evolution of the species during iterative rounds and confirmation
of enrichment was determined using flow cytometry using trans-
fected and non-transfected HEK293T cells (Fig. 1A). As shown in
Fig. 1B, round six showed a greater than 2.5-fold increase in bind-
ing to CD133-transfected HEK293T cells as compared to non-
transfected HEK293T cells and that of the unselected library.
Indeed, following round six, an almost complete loss of binding
species was observed. This could be due to a proportion of the
PCR amplicons being products of non-specific amplification which
bound to the target via non-specific binding. These amplicons are
preferentially amplified and possibly led to a decrease in the pro-
portion of binding species in subsequent rounds [35]. Round six
and round eleven were cloned and sequenced and a high propor-
tion of the clones from round eleven displayed truncated sequences.3.2. Post-SELEX engineering generated the smallest RNA aptamer
DNA from round six was cloned and sequenced and the clones
were fluorescently tagged with FITC using an in-house method.
The binding specificity of each clone was determined using
CD133-negative HEK293T cells and HEK293T cells transfected with
the expression construct of His-tagged CD133. The most encourag-
ing results were shown with two aptamers, designated CD133-A
and CD133-B (Fig. 2 A(i) and B(i)). These two clones were sequen-
tially truncated to determine the shortest number of bases re-Fig. 1. Isolation of CD133 aptamers using systematic evolution of ligands by exponential
from iterative rounds of SELEX to CD133-transfected HEK293T cells. Fluorescein-labelled
by flow cytometric analysis. (B) Comparison of the binding capacity of relative round
fluorescent intensity of the binding of unselected library RNA to target cells, as well as
random library.quired to maintain the structure of the binding region of the
aptamer (Fig. 2 and Table 1). Clone CD133-A was truncated a total
of four times to confirm the binding region of the aptamer (Fig. 2A
and Table 1). This clone was successfully truncated to 15 nucleo-
tides, making it the smallest published RNA aptamer against a can-
cer stem cell marker protein, and equivalent in size to the smallest
published DNA aptamer directed against thrombin [36]. A second
clone, CD133-B, was also investigated for its potential to bind with
high affinity and specificity to CD133. This aptamer was truncated
to 19 nucleotides (Fig. 2B(ii)), similar in size to our published apt-
amer targeting EpCAM [27]. In order for these CD133 aptamers to
become effective cancer targeting agents, they must have negligi-
ble interactions with cells that do not express CD133. Therefore,
both CD133-positive (HT-29 and Hep3B) and CD133-negative
(T98G and HEK293T) cell lines of human origin were used to study
the sensitivity and specificity of these two aptamers. As shown in
Fig. 3A and B, determination of the equilibrium dissociation con-
stant for both truncated aptamers showed a moderate binding
affinity with CD133-positive cancer cells (33.85–145 nM) (Table 2),
with the smallest aptamer, CD133-A15, having the better binding
affinity. These results are consistent with results observed from
previous experiments [27,37]. In addition, both aptamers did not
bind to CD133-negative cells (Fig. 3C and D. The specific interac-
tion between the CD133 aptamers was further verified using
CD133-positive and -negative cell lines. The cell line HT-29 was
used as a positive control to determine the specificity of our two
aptamers. As shown in Fig. 4, the interaction of our aptamers with
the different cell lines showed a similar staining pattern to that ob-
served with the AC133 antibody, thus confirming the specificity of
the aptamers.3.3. CD133-specific aptamers are internalised via receptor-mediated
endocytosis
For an aptamer to be developed into an effective cancer therag-
nostic, it must be efficiently internalised following binding to its
target [27,38,39]. We studied whether the newly isolated CD133enrichment (SELEX). (A) Flow cytometric binding analysis of FITC-labelled aptamers
RNA from each round was incubated with target cells at 37 C for 30 min, followed
s of SELEX. The binding of each round was calculated after subtracting the mean
that for binding to negative control cells. R, round in SELEX cycle; R0, unselected
Fig. 2. Post-selection engineering of CD133 aptamers. (A) CD133-A was serially truncated a total of four times (i: CD133-A; ii: CD133-A58, iii: CD133-A35, iv: CD133-A21, v:
CD133-A15); (B) CD133-B (i: was truncated once, ii: CD133-B19).
Table 1
Sequences of CD133 aptamers and their truncations.
Aptamer Sequence Base
pairs
CD133-A GAG ACA AGA AUA AAC GCU CAA CCC ACC CUC
CUA CAU AGG GAG GAA CGA GUU ACU AUA GAG
CUU CGA CAG GAG GCU CAC AAC
81
CD133-A58 GAG ACA AGA AUA AAC GCU CAA CCC ACC CUC
CUA CAU AGG GAG GAA CGA GUU ACU AUA G
58
CD133-A35 GCU CAA CCC ACC CUC CUA CAU AGG GAG GAA
CGA GU
35
CD133-A21 CC ACC CUC CUA CAU AGG GUG G 21
CD133-A15 CC CUC CUA CAU AGG G 15
CD133-B GAG ACA AGA AUA AAC GCU CAA GGA AAG CGC
UUA UUG UUU GCU AUG UUA GAA CGU AUA CUA
UUU CGA CAG GAG GCU CAC AAC AGG C
85
CD133-B19 CAG AAC GUA UAC UAU UCU G 19
88 S. Shigdar et al. / Cancer Letters 330 (2013) 84–95aptamers could internalise upon binding. To this end, we incubated
both CD133-positive and CD133-negative cells with CD133 apta-
mers at 37 C for 30 min followed by confocal microscopy. As
shown in Fig. 5A CD133 aptamers were efficiently internalised
upon binding. Such internalisation was specific as there was no
fluorescent signal in CD133-negative cell lines. Furthermore, we
confirmed that the mode of internalisation of CD133 aptamers
was via receptor-mediated endocytosis as the aptamer fluores-
cence was found outside the cells and displayed a ring pattern
along the plasma membrane upon the pre-treatment of endocytic
blockers, such as potassium-depletion and hypertonic treatments
(Fig. 5B). The effectiveness of these treatments in blocking recep-tor-mediated endocytosis has been previously confirmed using
transferrin as a positive control [27].3.4. CD133-specific aptamers are superior in penetrating tumour
spheres than CD133 antibodies
To study the effectiveness of our aptamers as cancer theranos-
tics, we investigated the potential of our aptamers to penetrate a
tumour mass using an in vitro 3-dimensional culture, tumour
sphere, as a model. We generated tumour sphere models of HT-
29 and HEK293T cell lines under ultralow attachment condition.
Upon reaching 200 lm in size, these spheres were incubated with
100 lM CD133-A15, CD133-B19 or 30 lM AC133 antibody. As pre-
sented in Fig. 6A, no tumour penetration was discernable with the
AC133 antibody even after 4 h incubation and limited penetration
was seen with our control RNA aptamer, which is of the same (19
nucleotide long) length as CD133-B19 but does not bind to CD133,
after 4 h incubation. In sharp contrast, a superior penetration into
the centre of the tumour sphere was seen with both our aptamers
from 30 min up to 4 h during our assay period. A moderately en-
hanced signal was seen from the CD133-B19 aptamer as compared
with CD133-A15. As well, only a weak signal was discernable with
the HEK293T tumour spheroids which served as a negative control
in this study (Fig. 6B). Importantly, 24 h after washing and further
incubation in sphere medium, the fluorescence signals for CD133
aptamers in the tumour sphere were clearly detectable (Fig. 6C),
demonstrating that the CD133 aptamers can not only penetrate
into the core of the tumour sphere but can also be retained by
the tumour cells in the centre of the sphere for at least 24 h.
Fig. 3. Determination of equilibrium dissociation constants (KD) for the interaction of truncated clones of CD133 aptamers with CD133 positive or negative cell lines.
Representative binding curves were determined at varying concentrations of CD133 aptamers (1–200 nM) using a cell density of 5  105 cells/mL. (A) HT-29 cells; (B) Hep3B
cells; (C) T98G cells; (D) HEK293T cells.
Table 2
CD133 dissociation binding constants against CD133-positive (HT-29 and Hep3B) and
CD133-negative (T98G and HEK293T) cells.
Cell line CD133-A15 KD (nM ± SEM) CD133-B19 KD (nM ± SEM)
HT-29 83.2 ± 82.9 145.1 ± 75.4
Hep3B 33.9 ± 12.5 52.3 ± 15.8
HEK293T >1000 >1000
T98G >1000 >1000
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the CD133 protein
As discussed, the AC133 epitope, instead of the entire CD133
protein, has been used as a marker of CSCs. Treatment with sodium
butyrate has been shown to differentiate colorectal cancer cells,
thus decreasing the expression of the AC133 epitope [40,41]. Using
the colorectal cancer cell line HT-29 as a model system, we studied
whether our CD133 aptamers could recognise both the AC133 epi-
tope and the non-AC133 extracellular segment of CD133 displayed
on the cancer cell surface. Following differentiation treatment with
sodium butyrate for 24 h, HT-29 cells were analysed by flow
cytometry to determine the binding epitope of our aptamers used
at 100 nM concentration. The binding of the AC133 antibody at
30 lM to the treated cells was used as a benchmark and showed
a 20% decrease in AC133-positive cells following treatment with
sodium butyrate for 24 h (Fig. 7A). These results are consistent
with previous reports showing a decrease in the AC133 epitope
during differentiation [5,7,40–43]. In parallel, the binding of the
CD133-A15 aptamer also showed a similar decrease in binding to
the differentiated HT-29 cells (Fig. 7A). Given that the level of bind-
ing of both the CD133-A15 aptamer and AC133 antibody decreases
with differentiation, it is plausible that this aptamer marks the
same population of cells as the AC133 antibody, the CSCs. In con-
trast, the binding of the other aptamer, CD133-B19, to the differen-
tiated HT-29 cells was increased, indicating that CD133-B19 binds
to the extracellular domain of the CD133 protein, but not the
AC133 epitope. Indeed, using another CD133 antibody which rec-ognises a spatially distinct epitope to AC133 [44], we confirmed
that there was no substantial change of the total CD133 protein le-
vel in the HT-29 cells before and after butyrate-induced differenti-
ation in a separate Western analysis (Fig. 7B and C).4. Discussion
Cancer stem cells (CSCs) are considered to be the root of cancer
responsible for cancer recurrence. This model has gained accep-
tance because it explains radiation- and chemotherapy-resistance
[45], and has led to numerous attempts to specifically target this
population of cells within the tumour. While there is not one spe-
cific marker which defines all CSCs, a number of markers, including
CD133, CD44, ALDH, EpCAM and ABCG2 [45,46], have proven use-
ful for defining the CSC population in solid tumours. CD133 has
been implicated as a marker of the CSC population in brain, pros-
tate, pancreas, melanoma, colon, liver, lung and ovarian cancers
[5], and it has been suggested to be the most important marker
of CSCs so far [47,48]. While the function of CD133 is yet to be elu-
cidated, this marker is upregulated in hypoxic conditions and has
been associated with vasculogenic mimicry in triple negative
breast cancer and prostate cancer [49,50], indicating the impor-
tance of CD133 in tumour growth and metastasis. As well, given
the conformational change that occurs during the differentiation
process, the AC133 epitope represents a unique target for the treat-
ment of various tumour types. Given how critical these CD133+
cells could be to the continuing spread of the tumour, we have iso-
lated RNA aptamers against CD133 that are 25–32 times smaller in
size than a monoclonal antibody.
We have previously described the success of our SELEX proce-
dures to isolate aptamers targeting another CSC marker [27]. The
isolation of aptamers targeting CD133 required a modification to
our protocol due to the pentaspan nature of this protein and the
necessity to use proteins in their physiological conformation for
selection of aptamers. The success of our selection protocol was
shown using flow cytometric binding assays, as well as RFLP anal-
ysis. Successful evolution was shown following the sixth SELEX cy-
cle, and several aptamers were cloned. Two aptamers were chosen
Fig. 4. Determination of specificity of CD133 aptamers. CD133-A15 or CD133-B19 were incubated at a concentration of 100 nMwith CD133-positive or -negative cell lines for
30 min at 37 C. Cells were also incubated with the AC133 antibody to confirm the presence of AC133 epitope. (A) HT-29 cells incubated with AC133-APC; (B) HT-29 cells
incubated with CD133-A15 and CD133-B19; (C) PA-1 cells incubated with AC133-APC; (D) PA-1 cells incubated with CD133-A15 and CD133-B19; (E) PLC/PCF/5 cells
incubated with AC133-APC; (F) PLC/PRF/5 cells incubated with CD133-A15 and CD133-B19; (G) A549 cells incubated with AC133-APC; (H) A549 cells incubated with CD133-
A15 and CD133-B19; (I) DU145 cells incubated with AC133-APC; (J) DU145 cells incubated with CD133-A15 and CD133-B19; (K) T47D cells incubated with AC133-APC; (L)
T47D cells incubated with CD133-A15 and CD133-B19. Black: Autofluorescence; Purple: AC133 antibody; Blue: CD133-A15 aptamer; Orange: CD133-B19 aptamer. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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tive cell lines. These aptamers were also truncated to determine
the minimal size required to maintain binding affinity. One of
our aptamers, CD133-A15 was truncated to a size of 15 bases. This
truncation makes this the smallest RNA aptamer described so far.
Both of these aptamers were shown to be sensitive and specific,and of more importance, these two aptamers were rapidly interna-
lised by receptor-mediated endocytosis following binding to their
target. This latter feature of the aptamers is a necessary require-
ment for these aptamers to be modified as theragnostic reagents.
Aptamers possess many benefits that make them ideal escort
modalities for both treatment and imaging of tumour masses. Their
Fig. 5. CD133 aptamers are endocytosed via receptor mediated endocytosis following binding to CD133-positive cells but not to CD133-negative cells. (A) DY647-labelled
CD133 aptamers were incubated with indicated cancer cells for 30 min at 37 C, followed by imaging using laser scanning confocal microscopy. (B) CD133 positive cells were
incubated with potassium depleted buffer to inhibit endocytosis. Transferrin or DY647-labelled CD133 aptamers were then incubated with HT-29 or Hep3B cells for 30 min at
37 C, followed by imaging using laser scanning confocal microscopy. Transferrin was used as a positive control to confirm inhibition of endocytosis. (C) HT-29 or Hep3B cells
were incubated with transferrin for 30 min at 37 C without endocytic inhibitors. Data are representative of three independent experiments. For each pair of panels,
fluorescent images are on the top, and optical (phase) images are on the bottom. Red: CD133 aptamer; blue: nuclear stain; green: transferrin. Scale bar = 20 lm. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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much more efficiently than conventional immunotherapy options,
and these nucleic acids also lack immunogenicity, leading to farfewer side effects. One of the problems associated with the use
of monoclonal antibodies for tumour therapy is the lack of penetra-
tion into the tumour mass. We have shown that our aptamers are
Fig. 6. CD133 aptamers show superior tumour penetration. AC133 antibody, CD133 aptamers or control aptamer were incubated with HT-29 or HEK293T tumour spheroids
for up to 240 min at 37 C. The tumour spheres were then washed three times in PBS and then either imaged using laser scanning confocal microscopy or incubated for a
further 24 h in PBS. (A) Antibody and aptamer staining of HT-29 cells; (B) Antibody and aptamer staining of HEK293T spheres for up to 240 min. Images are representative of
240 min incubation. (C) Following a 4 h incubation with CD133-A15 or CD133-B19, the HT-29 tumour spheroids were washed with PBS and incubated in PBS for 24 h and
imaged using laser scanning confocal microscopy. Scale bar = 200 lm.
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tained for a minimum of 24 h, suggesting that these aptamers
would act as ideal drug delivery modalities. In contrast, the
AC133 antibody was not capable of penetrating the tumour sphere
core, even at a 300-fold higher concentration than that for the
aptamers. This important property of the aptamers in this study
highlights the invaluable attribute of aptamers for molecular imag-
ing and targeted therapy. Not only are these aptamers internalised
efficiently within a short amount of time by the tumour cells, they
are also capable of penetrating the tumour mass, indicating their
potential to target all of the cells in the tumour, including those
that are usually poorly accessible due to their location in the tu-
mour core when used as a molecular imaging probe. Through addi-
tional functionalisation, either by direct conjugation to a
chemotherapeutic agent, e.g. doxorubicin or siRNA, or by surface
conjugation onto nanoparticles containing a drug cargo, aptamers
can function as very effective drug escorts [21]. While some apta-
mers can be effective solely by binding to their target, the majority
of aptamers are much more successful as targeting ligands to im-
prove the therapeutic index of cytotoxic agents. Therefore, by con-jugating chemotherapeutic drugs directly to the CD133 aptamers,
the drugs would not only be delivered to the tumour cells, but
would also be retained for a sufficient amount of time within the
tumour mass for the chemotherapeutic to kill the tumour cells.
We are currently investigating the effectiveness of functionalising
our aptamers for future theragnostic applications. Further studies
will be required to confirm that these aptamer-nanoparticle and
aptamer-drug constructs possess the same ability as aptamers to
penetrate the tumour mass.
It is important to distinguish between the CD133 protein and
the AC133 epitope when discussing the expression of either in
relation to CSCs. AC133 is generally considered to be the marker
of CSCs [51–53] though it should be pointed out that there is the
same heterogeneity in CSCs as seen in normal cancer cells [17].
While AC133 may be a marker of CSCs, not all CSCs express
AC133. There is also discordance over whether AC133 is truly a
CSC marker as studies have shown that both CD133+ and CD133
cells are capable of propagating tumours in mouse models [7–
10]. There are a number of reasons for this: there is a heterogeneity
in cell surface markers on CSCs [54,55]; the studies have used an
Fig. 7. CD133 aptamers bind to different epitopes. (A) HT-29 cells were incubated with 5 mM sodium butyrate for 24 h. The cells were then incubated with either the AC133
antibody, CD133-A15 or CD133-B19 aptamer for 30 min at 37 C. The cells were then washed three times prior to flow cytometric analysis. Graphical representation of at
least three independent experiments. Data are shown as means ± SEM. Statistically significant decrease. p = 0.05; (B) CD133 expression was confirmed by Western blotting
using the W6B3C1 antibody; (C) relative expression of CD133 was compared to b-actin.
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mine CD133 expression [56]; and the AC133 antibody is unable
to determine low expression or variants of the AC133 epitope so
a ‘negative’ AC133 cell population does not necessarily mean this
population of cells are not cancer stem cells [42,44,57]. It should
be noted, however, that differentiation studies examining the
expression of CD133 has consistently shown a down-regulation
in the expression of the AC133 epitope as compared to CD133
[40,41,43,58]. This data indicates that the AC133 is an important
marker of more primitive cells, such as CSCs. We examined if either
of our CD133 aptamers were able to distinguish this epitope versus
the CD133 protein using sodium butyrate differentiation treatment
of HT-29 cells. The AC133 antibody was used as a positive control
and showed a more than 20% decrease in expression levels follow-
ing 24 h treatment with 5 mM sodium butyrate. Interestingly, apt-
amer CD133-A15 also showed a similar decrease in cell binding,
indicating that this aptamer marks the same population of cells
as identified by the AC133 epitope. An additional antibody used
to confirm the expression of CD133 did not change following dif-
ferentiation treatment. This antibody recognises the same epitope
as AC133, and no significant decrease was observed following
treatment as determined by Western blot analysis. This has previ-
ously been reported to show that the AC133 epitope is masked
upon differentiation but is detectable by Western blot indicating
the cells still retain their CD133 protein. As well, no decrease
was seen in the percentage of positive cells recognised by aptamer
CD133-B19, indicating that this aptamer not only recognises a dif-
ferent epitope to CD133-A15, but is also capable of identifying dif-
ferentiated cancer cells. The use of both of these aptamers together
have the potential to target the bulk cancer cells and CSCs in a tu-
mour, thus reducing the bulk of the disease, as well as reducing the
metastatic potential at the same time. Indeed, it is becoming well
recognised that this is the only way we will successfully eradicate
cancer in the future [59].
An important aspect of aptamers in cancer research is their lack
of immunogenicity, a problem often encountered when antibodies
are used for therapeutics or for flow cytometric cell sorting prior to
xenotransplantation. A recent study demonstrated that the Fc-
fragment of antibodies can cause a profound inhibitory effect
on engraftment of tumour cells in xenograft models due toantibody-mediated clearance [60]. This study on antibody-coated
cells flow cytometrically sorted based on cell surface markers sug-
gests that the proportion of CSCs could be highly under-estimated
in xenotransplant studies using AC133 antibody-sorted cells. In
addition, a further study has suggested that by stimulating the im-
mune system, and thus targeting and attacking the bulk cancer
cells, a reduction in the size of the tumour results in an increase
in the proportion of CSCs [61]. These results taken together, along
with prior knowledge of the effect that the majority of therapeutic
antibodies have on the immune system, would indicate that
modalities other than antibodies are required both for research
into CSCs and also for the complete eradication of cancer in clinical
studies. Aptamers, which are identical to monoclonal antibodies in
their ability to bind to their targets with a high degree of selectiv-
ity, are superior to antibodies due to the lack of the Fc fragment
and thus devoid of an immune response when injected into
mammals. This attribute alone makes aptamers the ideal choice
for cancer therapeutics, in addition to be a valuable tool in cell
sorting for the isolation of CSCs. The ability to functionalise
these nucleic acids without loss-of-function is an added benefit.
As well, these aptamers do not suffer from the disadvantages
associated with other nucleic acid species, such as RNAi or anti-
sense oligonucleotides [21] due to their inability of entering the
target cells, as we select aptamers that are internalised upon
binding.
The targeting of CD133+ cells in certain tumour types would
seem to be a highly effective strategy to assist with the eradication
of cancer [62]. As CD133+ cells have been implicated in vasculogen-
ic mimicry, this could explain the lack of efficacy of anti-angiogenic
treatments, given that removing the oxygen supply from the tu-
mour increases the number of CD133+ cells. It is possible that by
combining the targeting of CD133+ cells continually alongside
anti-angiogenic therapy may increase the efficacy of these treat-
ments, though care must be taken that this does not increase the
invasiveness of the tumour. Further studies are required to deter-
mine the effectiveness of targeting CD133 cells alone, or in combi-
nation with other therapeutic options using the novel CD133 RNA
aptamers.
In summary, we have isolated the smallest RNA aptamer against
CD133. Our AC133-targeting aptamers represent the ideal
94 S. Shigdar et al. / Cancer Letters 330 (2013) 84–95molecules for the development of CSC targeted theranostics with-
out the sides effects associated with immunogenecity.Acknowledgements
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